AZD4045

AZD4045 is a CAR-T cell therapy developed by AstraZeneca. Its target is BCMA (the sponsor names BCMA). The sponsor states: An allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA). ClinicalTrials.gov describes the intervention as: Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT07681596, plans to enrol 101 participants with primary completion expected 2031-03-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.